Medical Research Technology Offers

Technology Categories

By Type

Covid-19 Innovation Challenges by Innoget posted this:

COVID-19 Rapid Diagnostic Kit Designing and developing vaccines, cures and diagnostic kits can be considered as the first priority for every country which is in the first line of fighting against coronavirus. Now there is only PCR test and IgG/IgM test for COVID-19 assessment. One of the most important problems of this diagnostic test is the time needed by the device to detect infected persons. This problem makes big companies in the field of pharmaceutical and medical devices manufacturing to design and develop rapid test kits. Our research team found that there are some specific proteins on the viral membrane which can make some reagents undergo a specific chemical reaction. Every reaction has a specific product related to substrates, so by detection of products with indicator reagents we are able to identify the virus in saliva. Indicator reagents usually change the reaction mixture color so by color change we can approve that the person is infected by COVID-19.

COVID-19 Rapid Diagnostic Kit

Alireza Daneshvar posted this:
Pharmacy Student and Researcher at Tehran University of Medical Sciences

COVID-19 Rapid Diagnostic Kit Designing and developing vaccines, cures and diagnostic kits can be considered as the first priority for every country which is in the first line of fighting against coronavirus. Now there is only PCR test and IgG/IgM test for COVID-19 assessment. One of the most important problems of this diagnostic test is the time needed by the device to detect infected persons. This problem makes big companies in the field of pharmaceutical and medical devices manufacturing to design and develop rapid test kits. Our research team found that there are some specific proteins on the viral membrane which can make some reagents undergo a specific chemical reaction. Every reaction has a specific product related to substrates, so by detection of products with indicator reagents we are able to identify the virus in saliva. Indicator reagents usually change the reaction mixture color so by color change we can approve that the person is infected by COVID-19.

COVID-19 Rapid Diagnostic Kit

TEC Edmonton posted this:

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors A series of small pharmacological molecules have been discovered to be potent and non-cytotoxic inhibitors of viral fusion. The inhibitors act on the non-virally encoded lipids in the virion envelope. These molecules are rigid amphipathic compounds of inverted cone shape which locate to the outer leaflets of virion envelopes, creating a physical barrier to viral envelope and cell membrane fusion. These amphipathic nucleoside derivatives can serve as potential antiviral or therapeutic agents against herpes, HIV, influenza, hepatitis B & C, poxvirus and other DNA or RNA enveloped viruses. They can potentially be used as prophylactic ingredients in creams, lotions, gels and as antiviral disinfectants.

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors

Covid-19 Innovation Challenges by Innoget posted this:

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors A series of small pharmacological molecules have been discovered to be potent and non-cytotoxic inhibitors of viral fusion. The inhibitors act on the non-virally encoded lipids in the virion envelope. These molecules are rigid amphipathic compounds of inverted cone shape which locate to the outer leaflets of virion envelopes, creating a physical barrier to viral envelope and cell membrane fusion. These amphipathic nucleoside derivatives can serve as potential antiviral or therapeutic agents against herpes, HIV, influenza, hepatitis B & C, poxvirus and other DNA or RNA enveloped viruses. They can potentially be used as prophylactic ingredients in creams, lotions, gels and as antiviral disinfectants.

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors

Lucas Montes posted this:
Technology Transfer Advisor at University of Granada (OTRI)

Multifunctionalized nanoparticles for cancer diagnosis and treatment A synthesis method of polymeric multifunctionalized nanoparticles has been developed. These nanoparticles have different agents that offer the ability to diagnose, treat and monitor different types of cancer specifically. Nowadays, functionalized nanoparticles are opening a wide range of opportunities to improve the diagnosis and treatment of different kind of pathologies. However, further studies are needed to optimize this nanosystem. In light of this, the present invention offers new efficient and versatile nanoparticles.

Yissum - Research Development Company of the Hebrew University posted this:

Novel Naturally Occurring Compounds for Treating Cystic Fibrosis Cannabis project Derivatives of cannabinoids have an antimicrobial and anti biofilm effect on pseudomonas and candida which are major ethological pathogenic factors in CF Project ID : 6-2019-6720

Ukrainian Laboratories posted this:

Computer aided drug discovery services Otava Research Institute helps researchers around the world develop advanced solutions for the variety of research projects maximizing their efficiencies, and, most of all, respecting their budgets. Our experts are involved in the development of leading compounds at any stage of the R&D process: starting from target identification to lead optimization

Computer aided drug discovery services

Consejo Superior de Investigaciones Científicas posted this:

Transphagocytic T cells as anti cancer immunotherapy Transphagocytic T cells as anti cancer immunotherapy CSIC´s research group, in collaboration with scientists from the Centre of Molecular Biology “Severo Ochoa” (CBMSO-CSIC), the Autónoma University of Madrid and the Health Research Institute of the “La Princesa” University Hospital, developed a new method for anti-cancer immunotherapy based on transphagocytic lymphocytes (tiCD4+ T cells) Companies interested in a patent license or investors for creation of a start-up are being sought. An offer for Patent Licensing

Transphagocytic T cells as anti cancer immunotherapy

Consejo Superior de Investigaciones Científicas posted this:

Overcoming resistance to Beta-lactam antibiotics in Bacterial species CSIC and the University of Würzburg have developed a new method to eliminate antibiotic-resistant bacterial infections using classical antibiotics previously discarded due the occurrence of antibiotic resistance. Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement. An offer for Patent Licensing

Overcoming resistance to Beta-lactam antibiotics in Bacterial species

Consejo Superior de Investigaciones Científicas posted this:

New treatment for epidermolysis bullosa and fibrosis CSIC, Carlos III University of Madrid and CIEMAT have repositioned drugs that stimulate endogline expression and modulate the TGF-β route for a new clinical use in the treatment of fibrosis, such as epidermolysis bullosa (EB). EB includes a heterogeneous group of rare hereditary diseases of the skin in which in its infantile incidence the patients are known as "butterfly children". It is a new therapy for a rare pathology, with potential in a wide spectrum of fibrosis, which would improve the possibilities of treatment of patients, improving their quality of life. Industrial partners from the pharmaceutical industry are being sought for its development in a wide variety of fibrotic pathologies through a patent licence agreement. An offer for Patent Licensing

New treatment for epidermolysis bullosa and fibrosis

Consejo Superior de Investigaciones Científicas posted this:

Kits for cell culture based on hydrogel coatings CSIC and Complutense University of Madrid have developed new kits for cell culture based on cytocompatible hydrogels coated onto stiff substrates. Due to the excellent adhesion of the hydrogel to these substrates is possible to have mechanically robust platforms, easy to handle as required in a cellular biology laboratory. These new kits have been successfully tested showing an excellent cellular proliferation on the surface of the hydrogel. Besides, this technology allows the detachment of a cell monolayer without the need of chemical or biological agents preserving the viability of cell harvesting. Industrial partners from the biotechnology with expertise in cell culture are being sought to collaborate through a patent license agreement. An offer for Patent Licensing

Kits for cell culture based on hydrogel coatings

Consejo Superior de Investigaciones Científicas posted this:

Biotechnological production of 11α hydroxylated steroids using recombinant bacteria.CSIC has developed a procedure for the biotechnological production of 11α hydroxylated steroids by generating and subsequent use of recombinant bacteria. These recombinant bacteria allow to perform microbial biotransformation processes that result in 11αhydroxylated steroid compounds from raw materials such as phytosterols and intermediate products efficiently and economically. These compounds have numerous applications in pharmacology. Companies are sought for implementing and commercializing the new technology under patent license agreement. An offer for Patent Licensing

Biotechnological production of 11α hydroxylated steroids using recombinant bacteria.

Consejo Superior de Investigaciones Científicas posted this:

Compounds for the treatment of optic neuritis CSIC and the University of Athens have found that secoiridoids, such as oleacein and oleocanthal, are useful to prevent or treat neuropathies that conduct to optic nerve injury, such as optic neuritis. A company dealing with pharmaceutical or nutraceutical compositions for ophtalmic applications is sought for licensing agreement. An offer for Patent Licensing

Compounds for the treatment of optic neuritis

Consejo Superior de Investigaciones Científicas posted this:

Peptide for cancer control linked to IL13R R R α α 2 2 o o v v e e r r e e x x p p r r e e s s s s i i o o n n CSIC has developed a peptide capable of inhibiting the signaling of IL-13 mediated by IL13Rα2. This peptide alone or within a nanoparticle or virus-like particles can be used in a pharmaceutical composition for the treatment of pathologies in which IL13Rα2 is overexpressed. This composition would be useful in the treatment and control of metastasis of colon cancer and other tumors (i.e glioblastoma), as well as in other pathologies such as asthma, atopic dermatitis or fibrosis. Industrial partners are being sought to develop and commercialized the products through a patent licence agreement. An offer for Patent Licensing

Peptide for cancer control linked to IL13R

Consejo Superior de Investigaciones Científicas posted this:

Piperidine derivatives for the control of Parkinson's and Alzheimer's CSIC has synthesized a series of piperidine derivatives that are capable of inhibiting the activity of the enzyme phosphodiesterase-8 (PDE8). This inhibitory activity makes them useful for the treatment of neurodegenerative diseases in which this enzyme is overexpressed. The compounds developed are, therefore, a new therapeutic alternative for Alzheimer's disease, and Parkinson, among others. Industrial partners from pharmaceutical industry are being sought to develop and commercialized the compounds through a patent licence agreement. An offer for Patent Licensing

Piperidine derivatives for the control of Parkinson's and Alzheimer's

1
2
3
4
5